Choi IJ, Lim S, Hwang Y, et al. - Researchers evaluated the prognostic worth of soluble neprilysin (sNEP) levels among patients experiencing ischemic heart disease. Participants were consecutive patients (n = 694) with coronary artery disease (CAD) receiving percutaneous coronary intervention (PCI). Among participants, measurements of neprilysin levels were obtained. The median sNEP level was identified to be 76.0 pg/ml. Patients with left ventricular ejection fraction (LVEF) ≥ 40% exhibited higher median sNEP levels as compared with those with LVEF < 40%. Findings demonstrated no link of serum sNEP levels with long-term death or cardiovascular outcomes following PCI in patients suffering from CAD. Raised sNEP levels may be related to a higher risk of all-cause mortality in the LVEF < 40% group.